Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT05065372RecruitingPhase 1
Metformin test with automated insulin in teens with type 1
This Phase 1 study tests how adding metformin affects blood flow in the kidneys, insulin sensitivity, and overall heart/metabolic health in young people with type 1 diabetes. It may help researchers understand whether this combo is safe and beneficial alongside automated or pump/shot insulin care.
Aurora, ColoradoAges 12–25 - NCT05067348RecruitingPhase 2
Tocilizumab for generalized myasthenia gravis symptoms
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT05070845RecruitingPhase 2
Study drug for immune thrombocytopenia with low platelets
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
Greenville, North CarolinaAges 18–70 - NCT05071222RecruitingPhase 1/Phase 2
Gene therapy trial for Artemis SCID using modified blood cells
This trial tests whether gene therapy can safely and effectively treat children with a specific type of severe combined immunodeficiency (SCID) caused by an Artemis gene problem. It uses the patient’s own stem cells, modifies them to add a missing gene, and then returns them after chemotherapy to help the new cells work.
ParisAges Up to 3.9 years - NCT05072691Recruiting
Tests spinal fluid proteins to predict multiple sclerosis outlook
This study checks specific proteins in spinal fluid to see whether they can predict how multiple sclerosis (or related symptoms like optic neuritis) may go over time. It may help doctors better estimate prognosis using results from tests you may already be having.
BrusselsAges 18 years+ - NCT05078957Recruiting
Study gut microbiome in older adults with well-controlled HIV
This trial studies how the bacteria in your gut (“microbiome”) relate to frailty (weakness/low physical resilience) in people with HIV who are stably doing well on treatment. It may help researchers understand why some people become frail and how the gut may play a role.
MarseilleAges 55 years+ - NCT05079282RecruitingPhase 1
Study drug for relapsed or treatment-resistant T-cell lymphoma
This early-phase (Phase 1) study tests ONO-4685 in adults whose T-cell lymphoma has come back or did not respond to treatment. It aims to find a safe dose and see whether it can shrink lymphoma in people with limited options.
Birmingham, AlabamaAges 18 years+ - NCT05089227RecruitingPhase 2
Long-term apixaban to prevent clots in autoimmune hemolytic anemia
This Phase 2 trial tests whether taking long-term apixaban (a blood thinner) can prevent venous blood clots in people with autoimmune hemolytic anemia (AIHA). It may help reduce the risk of dangerous clotting events if you meet safety and risk criteria.
DijonAges 18 years+ - NCT05091372RecruitingPhase 2
Maintenance treatment after transplant for newly diagnosed myeloma
This trial tests whether using belantamab mafodotin plus lenalidomide as long-term maintenance after an autologous stem cell transplant can keep multiple myeloma under control, guided by minimal residual disease (MRD). MRD is a very small amount of disease that may remain after transplant, and the study helps see if treating those patients better improves outcomes.
Houston, TexasAges 18 years+ - NCT05092191RecruitingPhase 2
Cannabis pill study for MS-related muscle stiffness
This Phase 2 trial tests whether cannabis can reduce muscle stiffness (spasticity) in people with multiple sclerosis. You may be able to participate if your stiffness is not improving with your current treatments.
Montreal, QuebecAges 21 years+ - NCT05093153Recruiting
Registry for adults with IgM blood protein conditions
This study is a registry that collects information about adults with certain IgM-related blood conditions. It may help doctors better understand these illnesses and improve future care.
Mérida, BadajozAges 18 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05092984RecruitingPhase 3
Spironolactone for rheumatoid arthritis with active symptoms
This trial tests whether spironolactone can reduce symptoms and inflammation in people with rheumatoid arthritis that is still active despite standard arthritis medicines. You may be able to join if your rheumatoid arthritis remains active and your current treatment plan has been stable for at least several months.
Strasbourg, AlsaceAges 18 years+ - NCT05099315Recruiting
Gut microbiome study in adults with severe eczema
This trial studies the gut microbiome in people with moderate to severe atopic dermatitis (eczema) who are starting or already receiving systemic (whole-body) treatment. It may help researchers understand what changes in gut bacteria are linked to eczema and to treatment response.
Berlin, State of BerlinAges 18 years+ - NCT05098821Recruiting
Study factors that affect eczema control on dupilumab
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
BerlinAges 18–75 - NCT05099471RecruitingPhase 2
Venetoclax plus rituximab for Waldenström’s macroglobulinemia
This Phase 2 study tests whether the combination of venetoclax and rituximab works better for Waldenström’s macroglobulinemia (WM) than expected from standard approaches. It is for adults with WM who have symptoms or organ/health problems caused by the disease.
BielefeldAges 18 years+ - NCT05100056Recruiting
Brentuximab for adults with Hodgkin’s lymphoma after stem cell plans
This study looks at how well brentuximab vedotin works for adults with Hodgkin’s lymphoma who have either already had, or are being considered for, stem cell transplant. It may help people who are receiving a specific treatment plan to control the lymphoma after transplant planning.
Wroclaw, DolnoslskieAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05110144RecruitingPhase 2
Testing two doses of two nerve pain medicines for chronic cough
This Phase 2 study tests whether two doses of duloxetine and amitriptyline can reduce symptoms in people with chronic cough that hasn’t responded to usual care. You may join to see if these medicines lessen cough severity over an 8-week blinded treatment period.
Rochester, MinnesotaAges 18–75 - NCT05112211Recruiting
Imaging study of doxycycline in thyroid eye disease
This study looks at how doxycycline (an antibiotic) affects thyroid eye disease using special imaging pictures. It may help doctors better understand disease activity and how well treatments work.
Guangzhou, GuangdongAges 18–70 - NCT05123443Recruiting
Study tracks iron changes in MS brain spots over time
This study looks at how “iron rims” in brain MRI scans change over time in people with multiple sclerosis (MS). It may help researchers understand MS activity better and how iron changes relate to disease progression.
NottinghamAges 16 years+ - NCT05124288Recruiting
Study immune changes after AML relapse after bone marrow transplant
This study looks at how the immune system changes when acute myeloid leukemia (AML) comes back after a donor stem cell transplant. It may help researchers create more personalized treatment plans and future guidelines for how to care for people in this situation.
Milan, MilanoAges 18 years+ - NCT05124600Recruiting
Personalized MS app study for 21-day daily use
This study looks at an individualized health eLibrary app for people with multiple sclerosis (MS). You may use the app for 21 days and help researchers compare outcomes between a group using the app and a comparison group.
Champaign, IllinoisAges 18 years+ - NCT05126147RecruitingPhase 4
Hydroxychloroquine for mild Graves’ eye swelling
This trial studies whether hydroxychloroquine can improve mild Graves’ orbitopathy (swelling and discomfort around the eyes). It’s meant for people with mild symptoms and who haven’t recently used certain eye or immune treatments.
HsinchuAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.